Preclinical study outlines cardiovascular side effects of breast cancer drug

July 13, 2016, University of Pennsylvania School of Medicine
A visualization of the coronary vasculature patterning of an adult mouse heart. Credit: Haig Aghajanian, PhD, Perelman School of Medicine at the University of Pennsylvania

A receptor protein that is the target of the breast cancer drug trastuzumab (Herceptin) is needed for proper heart blood-vessel development, reported researchers from the Perelman School of Medicine at the University of Pennsylvania. They published their findings this month in Nature Communications. These discoveries have implications for better understanding the cardiovascular side effects of trastuzumab commonly used for cancer and provide an example of integration at the molecular level of pathways involved in tissue growth and blood-vessel patterning.

First author Haig Aghajanian, PhD, a postdoctoral fellow in the lab of senior author Jon Epstein, MD, a professor of Cell and Developmental Biology and executive vice dean and chief scientific officer for Penn Medicine, showed that ErbB2, a growth factor receptor, is unexpectedly expressed by . Here it partners with neuropilin 1 to form a receptor for the vascular guidance molecule semaphorin 3d. Guidance molecules work by instructing the direction in which cells migrate, such as when new blood vessels are forming.

"ErbB2 is a well known target in cancer therapy, but not in vascular biology," Aghajanian said. "Our work identifies a new role for this important protein in blood vessel development and gives us a possible explanation for some of the cardiovascular associated with anti-ErbB2 therapies."

They found that the loss of semaphorin 3d leads to improper connections of the coronary veins forming within the developing heart. They found a similar effect when ErbB2 was lost from developing heart-vessel-lining cells, providing a genetic link between these pathways.

The team was surprised when ErbB2 came up in their search for molecular partners for semaphorin 3d because semaphorin guidance molecules are not typically known to work through ErbB receptors.

"We questioned ErbB2's role at first," Epstein said. (ErbB2 had not previously been shown to even be in blood vessels.) "But now these findings give us a possible explanation for why there can be serious cardiovascular side effects, including heart failure, in patients receiving anti-ErbB2 therapies such as Herceptin."

Aghajanian and Epstein are using this knowledge to refine the hypothesis that targeting ErbB2 may also affect heart blood vessels leading to unwanted side effects. A better understanding of why the deleterious side effects are produced may lead to better ways to monitor and detect these unwanted effects before they cause symptoms.

"This work adds to an array of signals that affect how vessels grow and offers more targets to develop that promote or block the growth of ," Epstein said. These new targets could have implications for stopping the growth of certain tumors, abating ischemia, and alleviating diabetic retinitis.

Explore further: Team discovers new mechanism of acquired resistance to breast cancer drugs

Related Stories

Team discovers new mechanism of acquired resistance to breast cancer drugs

February 2, 2015
In the search for new approaches to treat ERBB2 (also known as HER2) positive breast cancers that have become drug-resistant, Dartmouth's Norris Cotton Cancer Center investigator Manabu Kurokawa, PhD, led a team in discovery ...

Researchers identify mechanism that makes breast cancer invasive

March 29, 2012
A new study has identified a key mechanism that causes breast cancer to spread. The research, published by Cell Press on March 30th in the journal Molecular Cell, enhances our knowledge about the signals that drive cancer ...

Going to 'Wars' against cancer and heart disease

July 8, 2016
In a study conducted by Duke-NUS Medical School (Duke-NUS) and the National Heart Centre Singapore (NHCS), researchers discovered a new gene that controls blood vessel formation. This work presents a possible new drug target ...

Overcoming barriers in the quest to starve tumors of blood supply

July 13, 2016
One of the most exciting strategies researchers are pursuing for fighting cancer is to cut off the blood supply of cancerous cells. However, many initially-promising therapies have failed in part because tumor cells counteract ...

New treatment target identified for aggressive breast cancer

October 14, 2014
One of the first-known oncogenes has a protein partner that helps breast cancer proliferate and when it's blocked, so is the cancer, scientists report.

Newly engineered CAR T cells can better discriminate between cancer and normal cells

September 1, 2015
A new development in engineering chimeric antigen receptor (CAR) T cells, called affinity tuning, can make the CAR T cells spare normal cells and better recognize and attack cancer cells, which may help lower the toxicity ...

Recommended for you

Stem cell vaccine immunizes lab mice against multiple cancers

February 15, 2018
Stanford University researchers report that injecting mice with inactivated induced pluripotent stem cells (iPSCs) launched a strong immune response against breast, lung, and skin cancers. The vaccine also prevented relapses ...

Induced pluripotent stem cells could serve as cancer vaccine, researchers say

February 15, 2018
Induced pluripotent stem cells, or iPS cells, are a keystone of regenerative medicine. Outside the body, they can be coaxed to become many different types of cells and tissues that can help repair damage due to trauma or ...

Team paves the way to the use of immunotherapy to treat aggressive colon tumors

February 15, 2018
In a short space of time, immunotherapy against cancer cells has become a powerful approach to treat cancers such as melanoma and lung cancer. However, to date, most colon tumours appeared to be unresponsive to this kind ...

Can our genes help predict how women respond to ovarian cancer treatment?

February 15, 2018
Research has identified gene variants that play a significant role in how women with ovarian cancer process chemotherapy.

First comparison of common breast cancer tests finds varied accuracy of predictions

February 15, 2018
Commercially-available prognostic breast cancer tests show significant variation in their abilities to predict disease recurrence, according to a study led by Queen Mary University of London of nearly 800 postmenopausal women.

Catching up to brain cancer: Researchers develop accurate model of how aggressive cancer cells move and spread

February 15, 2018
A brief chat at a Faculty Senate meeting put two University of Delaware researchers onto an idea that could be of great value to cancer researchers.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.